Physician profile
Peter Alan Shriver
NPI 1457313371
$1,697.50
in general payments reported to CMS, 2019-2025
24 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $56.78 · 2021: $36.35 · 2022: $216 · 2023: $123 · 2024: $286 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $282.74 | 2019-2025 | Clareon, Tryptyr, Hydrus Microstent |
| Glaukos Corporation | $229.89 | 2022-2024 | Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Bausch & Lomb Americas INC. | $155.85 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Harrow Eye, LLC | $119.77 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $113.09 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $112.94 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $107.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $96.93 | 2019-2020 | |
| Dompe US, INC. | $76.34 | 2025 | Oxervate |
| Shire North American Group INC | $70.98 | 2019 | |
| Biotissue Holdings INC. | $47.37 | 2022-2023 | |
| Allergan, INC. | $41.20 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $34.35 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $24.43 | 2019 | |
| Rxsight INC | $22.41 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $21.58 | 2021 | |
| Rayner Intraocular Lenses Limited | $21.36 | 2025 | Omidria |
| Horizon Therapeutics Plc | $19.75 | 2023 | Tepezza |
| Carl Zeiss Meditec Cataract Technology INC. | $19.50 | 2019 | |
| Omeros Corporation | $17.96 | 2019 | |
| Oyster Point Pharma, INC. | $16.78 | 2024 | Ryzumvi, Tyrvaya |
| Coopervision INC. | $16.49 | 2022 | |
| Abbvie INC. | $14.78 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Shriver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.